Status:
COMPLETED
Stem Cell Infusion in the Treatment of Patients with Neurological Sequelae After Ischemic Stroke
Lead Sponsor:
Vinmec Research Institute of Stem Cell and Gene Technology
Conditions:
Ischemic Stroke
Eligibility:
All Genders
40-75 years
Phase:
PHASE1
PHASE2
Brief Summary
This trial is to investigate the safety and potential therapeutic efficacy of allogeneic administration of umbilical cord-derived MSCs (UC-MSCs) in combination with standard neurological complications...
Detailed Description
Stroke is the second leading cause of death behind ischemic heart disease worldwide. Traditional treatments have some limitations whereas preclinical data suggest that stem cell therapy is a promising...
Eligibility Criteria
Inclusion
- Age: from 40 to 75 years.
- Gender: either sex
- Patients have been discharged/patients who are hospitalized but their general condition is stable:
- No need for vasopressor drugs
- No need for mechanical ventilation or oxygen support
- No signs of infection (fever, high WBC, high CRP/Procalcitonin)
- No kidney failure, liver failure, heart failure.
- Time from onset to study participation ≤ 24 months
- National Institutes of Health Stroke Scale (NIHSS) score \>=5
- Agree to participate in the study
- Exclusion Criteria:
- Hematologic cause of stroke
- There is evidence of active infections, failure of heart, lung, liver, or kidney, respiratory distress syndrome, anemia, clotting disorder
- Cancer.
- Pregnancy.
- Tracheostomy, coma, complete quadriplegia, vegetative.
Exclusion
Key Trial Info
Start Date :
July 7 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 30 2023
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT05292625
Start Date
July 7 2020
End Date
November 30 2023
Last Update
January 6 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vinmec Research Institute of Stem Cell and Gene Technology
Hanoi, Hanoi, Vietnam, 100000